You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The firm recognized revenues in fiscal Q1 2019 of $11.5 million, driven by rapid growth in its NGS products as well as its synthetic biology business.
Alliance Global will distribute Mawi's iSWAB biosampling technologies to the Middle East, Africa, and parts of Central and South Asia.
The device can process high-volume sputum samples for PCR-based Mycobacterium tuberculosis detection at smear-negative, culture-positive levels.
The companies will join certain of their respective technologies into a single product for low-pass whole-genome sequencing and genotype imputation.
The Boston-based startup will use the funds to expedite prototype development of its sample preparation technology and computational approach.
Circulomics, Bionano, Sage Science, RevoluGen, and others have been developing methods for extracting DNA hundreds of kilobases and up to megabases in length.
The firms originally inked the agreement in 2015 and have now extended it until 2025.
The company plans to use the funding to further develop its Xdrop technology, which allows users to partition millions of single molecules in droplets.
CEO Brad Gray told investors at the JP Morgan Healthcare Conference that he believes the firm's GeoMx has advantages over competitors in the new market.
The round was led by Meritech Capital, with participation from Fidelity and Wells Fargo, and brings the company's total financing to date to $243 million.
Paragon and MGI Tech — a unit of BGI — have signed a distribution deal for certain of their respective next-generation sequencing panels and sample prep products.
Aside from its core synthetic biology business, the company has expanded into NGS and is looking to move into drug discovery and DNA data storage.
Twist, which went public in October, reported that its revenues doubled this year due to increased sales of its synthetic DNA products and the introduction of NGS products.
The company no longer plans to develop cell-free DNA assays for oncology but will instead look to commercialize a new target capture technology.
The company plans to add 150 to 200 new employees and is quadrupling its space in Pleasanton, California, including a manufacturing site for its microfluidic chips.
The company aims to position its platform as a validation tool for CRISPR-based therapeutics, while continuing to grow in the oncology space.
The startup plans to use the funds to scale its single-cell DNA analysis technology for blood-based cancer research and expand into CRISPR applications.
The method, called negative enrichment, protects DNA regions of interest prior to degrading the surrounding DNA, making the target fragments easier to read.
The life science research tools firm is offering 8,150,000 shares of its common stock at a price of $6.75 per share for gross proceeds of about $55 million.
The collaboration will use 1CellBio's InDrop system to examine inflammatory and immunological conditions in patients and develop disease profiles.
A German shepherd called Nala has had her genome sequenced.
A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?
Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.
In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.